Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.
Selonsertib在糖尿病腎病患者中的應用:一項2b期隨機主動進入臨床試驗。
J Am Soc Nephrol 2024-07-17
Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.
糖尿病患者慢性腎臟病進展的多模式努力。
J Diabetes Complications 2023-08-04
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
糖尿病腎病患者中間質幹細胞(ORBCEL-M)治療的安全性和初步療效:一項隨機臨床試驗(NEPHSTROM)。
J Am Soc Nephrol 2024-03-05
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
慢性腎臟病的醛固酮合成酶抑制及是否搭配 empagliflozin 的療效和安全性:一項隨機、對照的2期試驗。
Lancet 2024-02-01
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice.
慢性 empagliflozin 對糖尿病前期小鼠腎臟細胞代謝、結構和功能的初期變化。
Am J Physiol Cell Physiol 2024-04-15
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
非糖尿病患者中鈉葡萄糖共同轉運蛋白2抑制劑對慢性腎臟病進展的實際效果:有無白蛋白尿的患者。
Diabetes Obes Metab 2024-04-29